NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Serbian state pharma tender attracts only one valid bid

Published 2016-09-15, 07:25 a/m
© Reuters.  Serbian state pharma tender attracts only one valid bid
HG
-
BHC
-

BELGRADE, Sept 15 (Reuters) - A tender for a 25 percent stake in Serbia's loss-making, state-owned pharmaceutical company Galenika has attracted only one valid bid, the Economy Ministry said on Thursday.

Serbia has promised to sell, shut or slim down unprofitable state firms to fulfil the conditions of a 1.2 billion euro ($1.4 billion) loan deal with the International Monetary Fund, but bidders for generously-staffed, indebted companies have been hard to find.

Of three bids submitted for the company, which has debts of $220 million, only the one submitted by a Russian-British consortium for the minimum asking price of 7 million euros was valid, a state privatisation commission said. state companies for which Serbia is seeking buyers include the RTB Bor copper mine and the Resavica coal mine.

The consortium of Britain's Frontier Pharma and Russia's Petrovax Pharm promised to keep 700 jobs at Galenika's plant, the Economy Ministry said. The government has not yet decided whether to accept the bid or open talks with the consortium.

In April, Serbia sold its Zelezara Smederevo steel mill to China's Hebei Iron & Steel Group 000709.SZ for 46 million euros.

Of Galenika's $220 million debt, $50 million is owed to commercial banks and the rest to the state. A proposed $8.7 million sale of Galenika to Valeant VRX.TO failed in June 2013.

($1 = 0.8896 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.